The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Most patients with moderate to severe CD who did not initially respond to risankizumab achieved clinical response after extension. Delayed responders also demonstrated clinical and endoscopic ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...

In this uncontrolled study, patients with severe psoriasis (involved body surface area over 10%) were enrolled and treated with the IL-23 inhibitor risankizumab. Rather than the standard dose ...

Suggested remit: To appraise the clinical and cost effectiveness of spesolimab within its marketing authorisation for treating generalised pustular psoriasis flares in adults.